Notably, nab-paclitaxel, an HSA nanoparticle-based preparation of paclitaxel (another ABCB1 substrate [21]), which is approved for the treatment of different forms of cancer [32], had previously been shown not to avoid ABCB1-mediated drug efflux [33]. This evidence concerns the gene ALB and cancer.